Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.32 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13058551 | 0.84 | CXCR2 (0.36) | ALDH1A1TRPV4CXCR2 | |
| SCHEMBL19413483 | 0.82 | ALDH1A1 (0.35) | ALDH1A1TRPV4DRD2HTR2AHRH1 | |
| SCHEMBL22962276 | 0.81 | TRPV4 (0.35) | ALDH1A1TRPV4DRD2HTR2AHRH1 | |
| SCHEMBL12869001 | 0.81 | GABRA1 (0.42) | ALDH1A1TRPV4DRD2HTR2AHRH1 | |
| SCHEMBL10105645 | 0.78 | USP8 (0.33) | ALDH1A1TRPV4CXCR2 | |
| SCHEMBL12263092 | 0.78 | MAPT (0.38) | ALDH1A1EIF4A3KDM4EHPGD | |
| SCHEMBL13058538 | 0.76 | ALDH1A1 (0.53) | ALDH1A1DRD2HTR2AHRH1CXCR2 | |
| SCHEMBL186689 | 0.75 | TRPV4 (0.42) | ALDH1A1TRPV4KDM4EHPGDHSD17B10 | |
| SCHEMBL13748964 | 0.75 | TRPV4 (0.35) | ALDH1A1TRPV4DRD2HTR2AHRH1 | |
| SCHEMBL12049608 | 0.73 | CES2 (0.44) | EIF4A3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774775-B1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-10-11 | — | — | EP | disclosed |
| EP-3752498-B1 | SOMATOSTATIN MODULATORS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| US-10987359-B2 | Oxadiazepinone derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20210040087-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-11 | — | — | US | disclosed |
| US-20210024503-A1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-01-28 | — | — | US | disclosed |
| US-20200197408-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2020-06-25 | — | — | US | disclosed |
| WO-2019198024-A1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019157458-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987359-B2 | Oxadiazepinone derivatives and methods of treating hepatitis B infections | HCCS, SLC10A1, PYGL | ALDH1A1 554/4885TRPV4 4627/4885DRD2 2856/4885 |
| US-20230183219-A1 | CONDENSED SUBSTITUTED HYDROPYRROLES AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM3, CHRM2, CHRM4 | ALDH1A1 1756/4885TRPV4 464/4885DRD2 205/4885 |
| US-20210024503-A1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, CCNI, IRF3 | ALDH1A1 2920/4885TRPV4 4117/4885DRD2 3713/4885 |
| US-20210040087-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | ALDH1A1 4626/4885TRPV4 1233/4885DRD2 2265/4885 |
| US-20200197408-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HCCS, SLC10A1, PYGL | ALDH1A1 554/4885TRPV4 4627/4885DRD2 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.